Testing effectiveness (Phase 2)Looking for participantsNCT04588922
What this trial is testing
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Who this might be right for
Hematologic Malignancies
Sellas Life Sciences Group 160